3 days Ago By ABMN Staff
Wedbush Securities Inc. trimmed its holdings in MannKind Co. ( NASDAQ:MNKD – Free Report ) by 16.
7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Wedbush Securities Inc.
’s holdings in MannKind were worth $52,000 as of its most recent SEC filing. A number of other institutional investors also recently made changes to their positions in MNKD. 9258 Wealth Management LLC acquired a new stake in shares of MannKind during the 1st quarter valued at approximately $51,000.
Brookstone Capital Management acquired a new stake in shares of MannKind during the 2nd quarter valued at approximately $61,000. EntryPoint Capital LLC raised its position in shares of MannKind by 60.9% during the 1st quarter.
EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 9,008 shares in the last quarter. Mission Wealth Management LP raised its position in shares of MannKind by 18.2% during the 1st quarter.
Mission Wealth Management LP now owns 26,650 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 4,100 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of MannKind by 23.
9% during the 4th quarter. Victory Capital Management Inc. now owns 35,064 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 6,753 shares in the last quarter.
49.55% of the stock is owned by institutional investors and hedge funds. Insider Transactions at MannKind In other news, insider Stuart A.
Tross sold 25,000 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.26, for a total value of $156,500.
00. Following the completion of the transaction, the insider now owns 1,022,191 shares of the company’s stock, valued at $6,398,915.66.
The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . In related news, CEO Michael Castagna sold 85,106 shares of the firm’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.
30, for a total transaction of $536,167.80. Following the completion of the transaction, the chief executive officer now owns 2,294,836 shares of the company’s stock, valued at $14,457,466.
80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link . Also, insider Stuart A.
Tross sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $6.26, for a total value of $156,500.
00. Following the transaction, the insider now directly owns 1,022,191 shares of the company’s stock, valued at approximately $6,398,915.66.
The disclosure for this sale can be found here . Over the last quarter, insiders sold 197,997 shares of company stock valued at $1,245,912. 3.
00% of the stock is currently owned by corporate insiders. Wall Street Analysts Forecast Growth Get Our Latest Report on MNKD MannKind Stock Performance NASDAQ:MNKD opened at $6.27 on Monday.
MannKind Co. has a 1 year low of $3.17 and a 1 year high of $6.
44. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of 209.
07 and a beta of 1.32. The business has a fifty day moving average of $5.
65 and a 200-day moving average of $4.97. MannKind ( NASDAQ:MNKD – Get Free Report ) last released its quarterly earnings results on Wednesday, August 7th.
The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.
04. MannKind had a negative return on equity of 11.97% and a net margin of 4.
73%. The company had revenue of $72.39 million during the quarter, compared to analysts’ expectations of $64.
81 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share.
The company’s revenue for the quarter was up 48.9% compared to the same quarter last year. On average, equities research analysts predict that MannKind Co.
will post 0.11 EPS for the current year. MannKind Company Profile ( Free Report ) MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Featured Stories Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter .
.
